For biotechs nearing regulatory approval the key is to sell before launch. For buyers, playing the waiting game is a better strategy.
Celgene’s Revlimid ranks as biopharma’s most contested blockbuster, with a huge spread in future sales forecasts, while drugs from Bristol-Myers Squibb and Sanofi also…
A damning report by the US pricing watchdog Icer could bode ill for the uptake of Shire’s big hereditary angioedema hope.
Competition in the CGRP migraine space has left both Teva and Amgen willing to take hits on sales to hook new patients.
Alnylam has secured its first approval, but history suggests that launch will be far from easy.
Analysis of me-too drug approvals over time shows trends across therapy areas.
If the US drugs regulator picks up the pace in the second half of the year, 2018 could be a bumper year for novel medicine approvals.